Stolpa Weronika, Mizia-Malarz Agnieszka, Zapała Magdalena, Zwiernik Bartosz
Department of Oncology, Hematology, and Chemotherapy, Upper Silesia Children's Care Health Centre, Katowice, Poland.
Department of Pediatrics, Medical University of Silesia, Upper Silesia Children's Care Health Centre, Katowice, Poland.
Front Pediatr. 2023 Aug 22;11:1213009. doi: 10.3389/fped.2023.1213009. eCollection 2023.
CD34CD38 lymphoblasts as likely leukemia stem cells (LSCs) may be responsible for a worse response to treatment and may be a risk factor for recurrence in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
The study objective was to assess the prognostic role of CD34CD38 lymphoblasts in bone marrow on the day of BCP-ALL diagnosis.
115 patients with BCP-ALL, the median age of 4.5 years (range 1.5-17.9 years), gender: female 63 (54.8%) with BCP-ALL were enrolled; Group I ( = 90)-patients with CD34CD38 antigens and Group II ( = 20)-patients with CD34CD38 antigens on the lymphoblast surface.
A worse response on Days 8, 15, and 33 of therapy and at the end of treatment in Group II (CD34CD38) was more often observed but these differences were not statistically significant. A significantly higher incidence of BCP-ALL recurrence was in Group II.
1.In BCP-ALL in children, the presence of CD34CD38 lymphoblasts at the diagnosis does not affect the first remission.2.In BCP-ALL in children, the presence of CD34CD38 lymphoblasts at the diagnosis may be considered an unfavorable prognostic factor for disease recurrence.3.It is necessary to further search for prognostic factors in BCP-ALL in children.
CD34CD38淋巴母细胞作为可能的白血病干细胞（LSCs），可能是B细胞前体急性淋巴细胞白血病（BCP-ALL）治疗反应较差的原因，并且可能是复发的危险因素。
本研究旨在评估BCP-ALL诊断当天骨髓中CD34CD38淋巴母细胞的预后作用。
纳入115例BCP-ALL患者，中位年龄4.5岁（范围1.5 - 17.9岁），性别：女性63例（54.8%）；I组（n = 90）为淋巴母细胞表面有CD34CD38抗原的患者，II组（n = 20）为淋巴母细胞表面有CD34CD38抗原的患者。
II组（CD34CD38）在治疗第8天、15天、33天及治疗结束时的反应较差的情况更常出现，但这些差异无统计学意义。II组BCP-ALL复发的发生率显著更高。
